Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
XBIO 
Xenetic Biosciences Inc (XBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/10/2025: XBIO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.37% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.79M USD | Price to earnings Ratio - | 1Y Target Price 40 |
Price to earnings Ratio - | 1Y Target Price 40 | ||
Volume (30-day avg) 4833 | Beta 2.18 | 52 Weeks Range 2.45 - 5.20 | Updated Date 04/1/2025 |
52 Weeks Range 2.45 - 5.20 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-03-19 | When After Market | Estimate -0.2 | Actual -0.68 |
Profitability
Profit Margin -158.39% | Operating Margin (TTM) -169.41% |
Management Effectiveness
Return on Assets (TTM) -30.02% | Return on Equity (TTM) -50.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -2370102 | Price to Sales(TTM) 1.92 |
Enterprise Value -2370102 | Price to Sales(TTM) 1.92 | ||
Enterprise Value to Revenue 0.02 | Enterprise Value to EBITDA 1.03 | Shares Outstanding 1542140 | Shares Floating 1176806 |
Shares Outstanding 1542140 | Shares Floating 1176806 | ||
Percent Insiders 19.05 | Percent Institutions 6.44 |
Analyst Ratings
Rating 3 | Target Price 40 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xenetic Biosciences Inc
Company Overview
History and Background
Xenetic Biosciences Inc. is a biopharmaceutical company focused on developing novel therapies and technologies for unmet medical needs. Founded in 2003, the company has evolved through various strategic shifts, including a focus on oncology and immune-oncology.
Core Business Areas
- Oncology: Focus on developing biologic therapeutics for the treatment of cancer. The company's core technology involves using modified polysialic acid (PSA) to create novel drugs with improved therapeutic properties.
- Immuno-Oncology: Developing therapies that modulate the immune system to fight cancer, often involving combinations with other treatment modalities.
Leadership and Structure
The leadership team consists of a CEO, CFO, and other executives with expertise in drug development and commercialization. The organizational structure includes research and development, clinical operations, and business development functions.
Top Products and Market Share
Key Offerings
- ErepoXen: ErepoXen is a novel biologic designed to improve the treatment of anemia in chronic kidney disease patients. The competitor's are Amgen and Roche. Market Share data is limited due to product not commercialized.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Areas of growth include oncology and immuno-oncology.
Positioning
Xenetic Biosciences Inc. is a smaller player in the biopharmaceutical industry, focusing on niche areas within oncology. Its competitive advantage lies in its proprietary PSA technology.
Total Addressable Market (TAM)
The total addressable market for oncology therapies is estimated to be in the billions of dollars annually. Xenetic's positioning relative to this TAM is limited due to the company being in early-stage development with no approved products.
Upturn SWOT Analysis
Strengths
- Proprietary PSA technology platform
- Focus on unmet medical needs in oncology
- Experienced management team
- Potential for strategic partnerships
Weaknesses
- Limited financial resources
- Early-stage development pipeline
- Dependence on external funding
- Small market capitalization
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal development or acquisitions
- Positive clinical trial results leading to regulatory approval
- Increasing demand for novel oncology therapies
Threats
- Competition from larger pharmaceutical companies
- Failure to obtain regulatory approval for product candidates
- Unsuccessful clinical trials
- Changes in the regulatory landscape
Competitors and Market Share
Key Competitors
- AMGN
- RHHBY
Competitive Landscape
Xenetic Biosciences Inc. faces significant competition from larger, more established pharmaceutical companies with greater resources. The company's success depends on its ability to differentiate its products and secure partnerships.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company's focus on research and development rather than commercialization.
Future Projections: Future growth depends on successful clinical trials, regulatory approvals, and strategic partnerships.
Recent Initiatives: Recent initiatives include advancing product candidates through clinical trials and seeking partnerships for development and commercialization.
Summary
Xenetic Biosciences Inc. is a high-risk, high-reward biopharmaceutical company with a proprietary technology platform. The company's success is contingent on positive clinical trial results and securing strategic partnerships. Its limited financial resources and small market capitalization present challenges. The company faces stiff competition from larger players in the biopharmaceutical industry.
Similar Companies
AMGN
Amgen Inc
AMGN
Amgen Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xenetic Biosciences Inc
Exchange NASDAQ | Headquaters Framingham, MA, United States | ||
IPO Launch date 2014-06-30 | CFO, COO, Interim CEO & Corporate Secretary Mr. James F. Parslow | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.xeneticbio.com |
Full time employees 2 | Website https://www.xeneticbio.com | ||
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.